Hem Preparat/substans Diagnos/indikation Kontakt
A B C D E F G H I J K L M N O P Q R S T U V X Y Z Å Ä Ö

Referenser för Cernitol

 

Författare, artikel och publikation

År

 

Hämta abstract / fulltext

 

1. Antolak SJ Jr, Hough DM, Pawlina W, Spinner RJ. Anatomical basis of chronic pelvic pain syndrome: the ischial spine and pudendal nerve entrapment.
Med Hypotheses 2002; Sep; 59(3):349-53.

2002  

 

2. Aoki A, Naito K, Hashimoto 0, Yamaguchi M, Hara Y, Baba Y, et al. [Clinical evaluation of the effect of tamsulosin hydrochloride and cernitin pollen extract on urinary disturbance associated with benign prostatic hyperplasia in a multicentered study].
Hinyokika Kiyo 2002; 48 (5): 259-267.

 2002  

3. Ask-Upmark E. [A new method for the treatment of prostatitis.]
Sv Läkartidn. 1959; Jun 26; 56(26):1840-3.

 1959  

4. Bach D, Ebeling L. Möglichkeiten und Grenzen der Phytotherapie bei BPH: Behandlungsergebnisse mit Cernilton N in Stadium 1 - 3 nach Alken (bzw. II-IV nach Vahlensieck).
In: W. Vahlensieck and G. Rutishauser (Eds). Benigne Prostatopathien. G Thieme Stuttgart, 1992: pp 180 - 187.

 1992  

5. Becker H, Ebeling L. Conservative treatment of benign prostatic hyperplasia (BPH) with Cernilton N - Results of a placebo-controlled double-blind study.
Urologe (B) 1988; 28: 301-306.

 1988  

6. Becker H, Ebeling L. Phytotherapie of BHP with Cernilton N - results of a controlled prospective study.
In: W. Vahlensieck and G. Rutishauser (Eds). Benigne Prostatopathien. G Thieme Stuttgart, 1992: ​175-179.

 1992  

7. Bräuer H. The treatment of benign prostatic hyperplasia with phytopharmaka.
Therapiewoche 1986; 36: 1686-1696.

 1986  
8. Braun L, Peyer P, et al. Double-blind multicentre placebo-controlled study of the efficacy and tolerability of Adenoprostal in patients with benign prostatic hyperplasia (BPH).
Tribuna Medica Ticinese 1993; 58: 425-429.		 1993  
9. Buck AC, Cox R, Rees RW, Ebeling L, John A. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton. A double-blind, placebo-controlled study.
Br J Urol 1990; 66 (4): 398-404.		 1990  
10. Buck AC, Rees RW, Ebeling L. Treatment of chronic prostatitis and prostatodynia with pollen extract.
Br J Urol. 1989; Nov; 64(5):496-9.		 1989  
11. Clemens JQ, Meehan RT, O'Keeffe Rosetti MC, Gao SY, Calhoun EA. Incidence and clinical characteristics of National Institutes of Health type III prostatitis in the community.
J Urol. 2005; Dec; 174(6):2319-22.		 2005  
12. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG: MTOPS RESEARCH Group. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.
J Urol. 2006; Apr; 175(4):1422-6.		 2006  

13. De la Rosette JJ, Alivizatos G, Madersbacher S, Perachino M, Thomas D, Desgrandchamps F

et al. EAU Guidelines on benign prostatic hyperplasia (BPH).
Eur Urol 2001; 40 (3): 256-263.

 2001  
14. Dellabella M, Milanese G, Muzzonigro G. Correlation between ultrasound alterations of the preprostatic sphincter and symptoms in patients with chronic prostatitis-chronic pelvic pain syndrome.
J Urol. 2006; Jul; 176(1): 112-8.		 2006  
15. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis.
Eur Urol 2003; Feb;43(2):164-75.		 2003  
16. Dutkiewicz S. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.
Int Urol Nephrol 1996; 28 (1): 49-53. 		1996  
17. Eaton CL. Aetiology and pathogenesis of benign prostatic hyperplasia.
Curr Opin Urol 2003 Jan;13(1):7-10. 		2003  
18. Ebeling L. Therapeutic results of defined pollen-extract in patients with chronic prostatitis or BPH accompanied by chronic prostatitis.
Presentation at the 3rd International Conference on Prostato - Urethritis. September 5 - 7, 1985.		 1985  
19. Erickson BA, Jang TL, Ching C, Schaeffer AJ. Chronic prostatitis.
Clin Evid 2006 Jun; (15):1252-62.		 2006  

20. Fall M, Baranowski AP, Fowler CJ, Lepinard V, Malone-Lee JG, Messelink EJ et al. EAU Guidelines on chronic pelvic pain.
Eur Urol 2004 Dec; 46(8):681-9.

 2004  
21. Gerstenbluth RE, Seftel AD, MacLennan GT, Rao RN, Corty EW, Ferguson K, Resnick MI. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation.
J Urol 2002 May; 167(5):2267- 70.		 2002  
22. Gonzalez RR, Te AE. Chronic prostatitis and sensory urgency: whose pain is it?
Curr Urol Rep 2004 Dec; 5(6):437-41.		 2004  

23. Habermacher GM, Chason JT, Schaeffer AJ. Prostatitis/chronic pelvic pain syndrome. Annu Rev Med 2006;57:195-206.

 2006  

24. Hess R. 2060 Cernitin T60, 2065 Cernitin GBX. Assessment of sensitising potential. Scientific report, November 3, 1992.

 1992  
25. Jodai A, Maruta N, Shimomae E, Sakuragi T, Shindo K, Saito Y. A long-term therapeutic experience with Cernilton in chronic prostatitis.
Acta Urol Jpn 1988 Mar; 34(3):561-8.		 1988  
26. Karlovsky ME, Pontari MA. Theories of prostatitis etiology.
Curr Urol Rep 2002; Aug;3(4):307-12.		 2002  

27. Kawakami J, Siemens DR, Nickel JC. Prostatitis and prostate cancer: implications for prostate cancer screening.
Urology 2004; 64 (6): 1075-1080.

 2004  
28. König JE, Senge T, Allhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
Prostate 2004; Feb 1;58(2):121-9.		 2004  
29. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia?
Curr Opin Urol 2006 Jan; 16(1):25-9. 		 2006  
30. Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia.
J Urol 2004 Nov; 172(5 Pt 1):1784-91.		 2004  

31. Lowe FC, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, O'Leary M, Perez M, Speakman M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion.
Prostate Cancer Prostatic Dis. 2005; 8(3):206-9.

 2005   
32. Mac Donald R, Ishan A, Rutks I, Wi It Tj. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia.
BJU International 1999; 85: 836-841.		 1999  
33. Maekawa M, Kishimoto T, Yasumoto R, Wada S, Harada T, Ohara T, et al. [Clinical evaluation of Cernilton on benign prostatic hypertrophy--a multiple center double-blind study with Paraprost].
Hinyokika Kiyo 1990; 36 (4): 495-516.		 1990  
34. Martinez-Borges AR. Turbulent urinary flow in the urethra could be a causal factor for benign prostatic hyperplasia.
Med Hypotheses 2006; 67(4):871-5. Epub 2006 Jun 9.		 2006  
35. Mazzi R, Bolognini G, Gilardi S, Pani T. Results of an open trial with FH84 (Cernitin pollen extract) in patients with pollinosis.
Study Report, 1986.		 1986  
36. Mehik A, Leskinen MJ, Hellstrom P. Mechanisms of pain in chronic pelvic pain syndrome: influence of prostatic inflammation.
World J Urol 2003 Jun; 21(2):90-4. Epub 2003 Apr 17.		 2003  
37. Mirone V, Imbimbo C, Sessa G, Palmieri A, Longo N, Granata AM, Fusco F. Correlation between detrusor collagen content and urinary symptoms in patients with prostatic obstruction.
J Urol 2004 Oct; 172(4 Pt 1):1386-9.		 2004  
38. Monden K, Tsugawa M, Ninomiya Y, Ando E, Kumon H. [A Japanese version of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI, Okayama version) and the clinical evaluation of cernitin pollen extract for chronic non-bacterial prostatitis].
Nippon Hinyokika Gakkai Zasshi 2002; 93 (4): 539-547.		 2002  
39. Mullan RJ, Bergstralh EJ, Farmer SA, Jacobson DJ, Hebbring SJ, Cunningham JM, Thibodeau SN, Lieber MM, Jacobsen SJ, Roberts RO. Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men.
Urology 2006 Feb; 67(2):300-5.		 2006  
40. Nakai H, Yamanishi T, Yasuda K, Kitahara S, Suzuki T. Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia.
Neurourol Urodyn 2004; 23(7):618-22.		 2004  
41. Nickel JC, Berger R, Pontari M. Changing paradigms for chronic pelvic pain: a report from the chronic pelvic pain/chronic prostatitis scientific workshop, October 19-21, 2005, Baltimore, MD.
Rev Urol 2006 Winter;8(1):28-35.		 2006  

42. Nickel JC, Bostwick, DG, Allen G, Sommerville MC, Rittmaster R. Lack of relationship between clinical prostatitis and prostate inflammation: baseline data from the REDUCE trial.
Abstract No. 97 of the American Urological Association Annual Meeting, Atlanta, Georgia, USA, May 20-25, 2006. J Urol 2006 Apr;175(4 Suppl).

 2006  
43. Nickel JC, Elhilali M, Vallancien G; ALF-ONE Study Group. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH.
BJU Int 2005 Mar; 95(4):571-4.		 2005   
44. Nickel JC, Teichman JM, Gregoire M, Clark J, Downey J. Prevalence, diagnosis, characterization, and treatment of prostatitis, interstitial cystitis, and epididymitis in outpatient urological practice: the Canadian PIE Study.
Urology 2005; 66 (5): 935­940.		 2005  
45. Nickel JC. The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis.
Curr Opin Urol 2006; 16 (1): 5-10. 		2006  
46. Parsons CL. Prostatitis, interstitial cystitis, chronic pelvic pain, and urethral syndrome share a common pathophysiology: lower urinary dysfunctional epithelium and potassium recycling.
Urology 2003 Dec; 62(6):976-82.		 2003  

47. Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S. Carini M. Giubilei 0, Fibbi B, Colli E, Maggi M, Adorini L. Seminal Plasma Cytokines and Chemokines in Prostate Inflammation: Interleukin 8 as a Predictive Biomarker in Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Benign Prostatic Hyperplasia.
Eur Urol 2006 Jul 28; [Epub ahead of print]

 2006  

48. Pham H, Banerjee T, Ziboh VA. Suppression of cyclooxygenase-2 overexpression by 15S-hydroxyeicosatrienoic acid in androgen-dependent prostatic adenocarcinoma cells.
Int J Cancer 2004 Aug 20; 111(2):192-7.

 2004  

49. Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome.
Urol. 2004 Sep; 172(3):839-45.

 2004  
50. Potts JM. Chronic pelvic pain syndrome: a non-prostatocentric perspective.
World J Urol 2003 Jun; 21(2):54-6. Epub 2003 Apr 4.		 2003  

51. Prezioso D, Naber KG, Loberl B, Weidner W, Algaba F, Denis LJ, Griffiths K. Changing concepts on prostatitis.
Arch Med Sci 2006; 2(2): 71-84.

 2006  
52. Propert KJ, Litwin MS, Wang Y, Alexander RB, Calhoun E, Nickel JC, O'Leary MP, Pontari M, McNaughton-Collins M. Chronic Prostatitis Collaborative Research Network (CPCRN). Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI).
Qual Life Res 2006 Mar;15(2):299-305.		 2006  

53. Propert KJ, McNaughton-Collins M, Leiby BE, O'Leary MP, Kusek JW, Litwin MS. Chronic Prostatitis Collaborative Research Network. A prospective study of symptoms and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome:
the National Institutes of Health Chronic Prostatitis Cohort study.
J Urol 2006 Feb;175(2):619-23.

 2006  
54. Roehrborn CG, Kaplan SA, Noble WD, Lucia MS, Slavin KM, McVary KT, Kusek JW, Nyberg LM Jr. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. Abstract No. 1277 of the American Urological Association Annual Meeting. May 21-26, 2005, San Antonio, Texas, USA.
J Urol 2005 Apr;173(4 Suppl).		 2005  
55. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III).
Prostate 2005 Jan 1;62(1):27-33.		 2005  
56. Rugendorff EW, Weidner W, Ebeling L, Buck AC. Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia.
Br J Urol 1993; 71 (4): 433-438.		 1993  
57. Schaeffer AJ, Datta NS, Fowler JE Jr, Krieger JN, Litwin MS, Nadler RB, Nickel JC, Pontari MA, Shoskes DA, Zeitlin SI, Hart C. Chronic Prostatitis Collaborative Research Network. Overview summary statement. Diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Urology 2002 Dec;60(6 Suppl):1-4. 2002  

58. Schneider H, Ludwig M, Horstmann A, Schnitker J, Weidner W. The efficacy of Cemilton in patients with chronic pelvic pain syndrome (CP/CPPS) type NIH III: A randomized, prospective, double-blind, placebo controlled study.
Poster 105, AUA Meeting 2006, May 20-25, Atlanta, Georgia, USA.

 2006  
59. Schneider H, Ludwig M, Horstmann A, Schnitker J, Weidner W. The efficacy of Cernilton in patients with chronic pelvic pain syndrom (CP/CPPS) type NIH lila: A randomized, prospective, double-blind, placebo controlled study.
J Urol 2006; 175 (4): 34. AUA Meeting Program Abstracts 2006.		 2006  
60. Schneider H, Wilbrandt K, Ludwig M, Beutel M, Weidner W. Prostate-related pain in patients with chronic prostatitis/chronic pelvic pain syndrome.
BJU Int 2005 Feb ;95(2):238 - 43.		 2005  

61. Schnitker J, Koch H-F, Paal 0. Biometric analysis of a retrospective documentation study of Cernilton N in the treatment of patients with chronic symptomatic prostatitis.
Study report, 18.03.1991.

 1991  
62. Schulz V, Hänsel R. 6.2.4 Gräserpollen.
In: Rationale Phytotherapie. Ratgeber fur die ärztliche Praxis. 4th Edition, Springer Berlin, 285-6, 1999.		 1999  
63. Shoskes DA, Manickam K. Herbal and complementary medicine in chronic prostatitis.
World J Urol 2003 Jun;21(2):109-13. Epub 2003 Apr 29.		 2003  

64. Suzuki T, Kurokawa K, Mashimo T, Takezawa Y, Kobayashi D, Kawashima K, Totsuka Y, Shiono A, Imai K, Yamanaka H. Clinical effect of Cernilton in chronic prostatitis.
Acta Urol Jpn 1992 Apr;38(4):489-94.

 1992  
65. Takeuchi H, Yamauchi A, Ueda T, Hiraga S. Quantitative evaluation on the effectiveness of Cernilton on benign prostatic hypertrophy.
Acta Urol Jpn 1981; 27: 371.		 1981  

66. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling.
Exp Gerontol 2005 Mar;40(3):121-8. Epub 2005 Jan 22.

 2005  
67. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium.
Prostate 2004 Sep 15;61(1):60-72.		 2004  
68. Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia (review).
Cochrane Database of Systematic Reviews CD001042.2006.		 2006  
69. Wiygul RD. Prostatitis: epidemiology of inflammation.
Curr Urol Rep 2005 Jul;6(4):282-9.		 2005  
70. Yamaguchi 0, Shiraiwa Y, Kobayashi M, Yokota T, Ohinata M, Aoki H, et al. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study.
Urol Int 1990; 45 Suppl 1: 40-46. 		1990  
71. Yasumoto R, Kawanishi H, et al. Clinical evaluation of long-term treatment using Cernitin pollen extract in patients with benign prostatic hyperplasia.
Clinical Therapeutics 1995; 17: 82-87.		 1995  
72. Zhou JF, Xiao WQ, Zheng YC, Dong J, Zhang SM. Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis.
Asian J Androl 2006 May;8(3):317-23.		 2006   
     
     
     

 

  

Scientific Communication AB | Köpenhamnsvägen 93 E | 21775 Malmö | Tel: 040 120105 | E-post: info@scicom.se